Study identification

PURI

https://redirect.ema.europa.eu/resource/48417

EU PAS number

EUPAS44606

Study ID

48417

Official title and acronym

Prospective observational study of Fremanezumab (Ajovy™) effectiveness in chronic and episodic migraine patients in clinical routine: FINESSE study

DARWIN EU® study

No

Study countries

Austria
Germany

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Xenia Hamann

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Teva GmbH
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable